The Global Health Body Raises Alert Over Severe Scarcity of Weight-Loss Medications

Under 10% of people that would benefit from weight-loss injections such as Wegovy have access to them, states the WHO as it publishes its initial guidance on the drugs.

Given in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for more widespread and fairer availability to this class of drugs.

Per forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.

"Our latest guidance acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and supply-chain constraints are major obstacles to universal availability to the injections that can aid individuals in losing substantial body mass, explains the organization.

Skinny Jab Scarcity

Even under the present best projected scenario, the supply of such drugs would only suffice for around 100 million people – under 10% of eligible patients, per the WHO.

The recommendation urges governments and firms to widen access, via approaches such as voluntary licensing.

A patent on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in several countries in 2026.

The Way Weight-Loss Drugs Function

GLP-1 drugs replicate a natural hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so individuals reduce food intake.

People typically start to lose weight after several weeks of commencing the regular doses.

Research suggests patients may regain a significant portion within a year of halting the medication, when their typical appetite resume.

Being overweight or obese increases your likelihood for developing diseases, such as diabetes, cardiovascular issues, stroke, and some malignancies.

Excess weight impacts people in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.